Eli Lilly Secures $2.25B AI Gene-Editing Deal, Faces Q1 Options Volatility
Eli Lilly struck an exclusive AI gene-editing collaboration with Profluent worth up to $2.25 billion, securing milestone-based payments for any CRISPR-derived therapies. Shares have slid over 20% since January while implied volatility on options hit multi-month highs, setting up a potential post-Q1 earnings squeeze as vol collapses.
1. AI Collaboration with Profluent
Eli Lilly has signed an exclusive partnership with AI startup Profluent valued at up to $2.25 billion, granting Lilly sole rights to any drug candidates developed via advanced CRISPR gene-editing models. Payments are structured around undisclosed milestone achievements, aiming to leverage Profluent’s large-sequence insertion technology trained on extensive protein datasets to design disease-specific therapies.
2. Bearish Options Positioning Ahead of Earnings
Lilly shares have declined more than 20% since January, driven in part by extremely bearish options positioning and elevated implied volatility. With Q1 earnings approaching, implied vol is expected to plunge, which could force put holders and market makers to unwind bearish bets, potentially applying upward pressure on the stock post-report.